secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-10-31T23:59:59+00:00
Accession:  0001493152-25-020390
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics sells 75% stake in Nova Cell subsidiary for $6M; expects $0.5M annual cost savings
--------------------------------------------------------------------------------

- Sold 22.5M shares (100% of its Nova Cell ownership) for $6M; consideration includes debt cancellation of ~$1.2M and deferred payments.
- Nova Cell ceases to be a subsidiary; Calidi expects $0.5M/year in G&A expense reductions.
- Company retains cell lines for own use; Nova Cell assumes certain liabilities and is prohibited from oncolytic virus uses.
- Calidi also terminates prior IP assignment agreement with Nova Cell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/0001493152-25-020390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-020390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer